BEAM:通过多源可交换性建模实现自适应样本量的贝叶斯混合设计
BEAM是一种贝叶斯混合设计,利用改进的多源可交换性模型动态借用多个历史数据源的信息,并在试验过程中自适应调整样本量。模拟显示其在控制I类错误率、减少偏倚和保持把握度方面表现稳健。该设计还通过强直性脊柱炎案例研究进行了说明。
要点
- BEAM设计通过多源可交换性建模动态借用多个历史数据源的信息。
- 该设计在试验过程中自适应调整样本量,以保持统计严谨性和效率。
- 模拟显示BEAM在控制I类错误率、减少偏倚和保持把握度方面表现稳健。
核心结论
- BEAM设计能在当前与历史数据存在异质性时保持统计严谨性和效率,并缓解对照组招募和依从性挑战。
研究设计与样本
- BEAM是一种贝叶斯混合设计,整合外部数据源(如历史对照和真实世界数据),通过改进的多源可交换性模型动态借用信息并自适应调整样本量。
- 通过广泛模拟评估BEAM的性能,并在强直性脊柱炎案例研究中展示其应用。
主要发现
- 模拟显示BEAM在控制I类错误率、减少偏倚和保持把握度方面优于传统方法和其他自适应设计。
- BEAM提供了灵活高效的计算框架,有助于降低药物开发成本和时间。
- 在强直性脊柱炎案例研究中展示了BEAM设计的应用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Randomized controlled trials (RCTs) are considered the gold standard for evaluating treatment efficacy, but they come with several practical challenges. These include high costs, lengthy timelines, ethical concerns for participants in placebo or control arms, and issues such as patient attrition and non-compliance. Recruiting patients for the control arm can be particularly challenging, especially in therapeutic areas with high unmet medical needs. To address these issues, hybrid trial designs that integrate external data sources, such as historical controls and real-world data, have emerged as a promising alternative. This paper introduces the Bayesian hybrid design with adaptive sample size through multisource exchangeability modeling (BEAM). The BEAM design leverages a modified multisource exchangeability model to dynamically borrow relevant information from multiple historical data sources, while adaptively adjusting the sample size throughout the trial. This approach ensures that the trial maintains statistical rigor and efficiency, even when heterogeneity exists between current and historical data, and mitigates the challenges associated with control arm accrual and compliance. Through extensive simulations, BEAM demonstrated robust performance in controlling type I error rate, reducing bias, and maintaining power compared to traditional methods and other adaptive designs. Additionally, the BEAM design offers a versatile and efficient computational framework for optimizing clinical trials, helping to reduce both the cost and time involved in drug development. We also illustrate the application of the proposed BEAM design in a case study on ankylosing spondylitis.
引用
- Tian F, Liu M, Zhao Y, et al. BEAM: Bayesian Hybrid Design With Adaptive Sample Size Through Multisource Exchangeability Modeling. Stat Med. 2025. PMID: 40474447. doi:10.1002/sim.70137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。